Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8272741 | 1.00 | RPS6KB1 (0.43) | RPS6KB1KDM1AMAOAMAPK1HDAC2 | |
| SCHEMBL17846454 | 0.81 | RPS6KB1 (0.51) | RPS6KB1KDM1AMAOAMAPK1HDAC2 | |
| SCHEMBL27687082 | 0.81 | KDM1A (0.45) | RPS6KB1KDM1AMAOAMAPK1HDAC2 | |
| SCHEMBL18247761 | 0.78 | PKM (0.42) | — | |
| SCHEMBL14428330 | 0.78 | PKM (0.42) | — | |
| SCHEMBL486028 | 0.78 | F2R (0.56) | MAOA | |
| SCHEMBL5241303 | 0.77 | KDM1A (0.55) | RPS6KB1KDM1AMAPK1 | |
| Trifluoroacetic Acid SCHEMBL10006604 | 0.77 | CHRNA7 (0.47) | KDM1AJAK3BACE1 | |
| Acetic Acid SCHEMBL30325545 | 0.76 | HPSE (0.41) | — | |
| SCHEMBL3554554 | 0.75 | HPSE (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773805-A1 | QUINAZOLIN-4-YL-PIPERIDINE AND CINNOLIN-4-YL-PIPERIDINE DERIVATIVES AS PDE10 INHIBITORS FOR THE TREATMENT OF CNS DISORDERS | Pfizer Products Incorporated (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006011040-A1 | QUINAZOLIN-4-YL- PIPERIDINE AND CINNOLIN-4-YL- PIPERIDINE DERIVATIVES AS PDE10 INHIBITORS FOR THE TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060019975-A1 | Novel piperidyl derivatives of quinazoline and isoquinoline | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019975-A1 | Novel piperidyl derivatives of quinazoline and isoquinoline | PDE5A, PDE4A, PDE3A | RPS6KB1 3732/4885KDM1A 1530/4885MAOA 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.